Talphera, Inc.
TLPHTalphera, Inc. in brief
Talphera, Inc. is a listed company in the Pharmaceutical industry, based in California, USA. It was founded in 2005. Its market value was $57 M on 29 October 2026, which makes it the 20,851st largest listed company in the world and the 3,807th largest in the USA on this site. In the year to December 2025 it had sales of $5 M and a net loss of $40 M. It employs about 12 people. Its shares trade under the symbol TLPH (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Talphera, Inc.
Our portfolio is principally focused on our lead product candidate, Niyad (nafamostat mesylate), for use as a regional anticoagulant during continuous renal replacement therapy, or CRRT. In addition, we may develop LTX-608, a nafamostat formulation for direct IV infusion for one or more of the following indications: disseminated intravascular coagulation, or DIC, acute respiratory distress syndrome, or ARDS, acute pancreatitis, or as an anti-viral treatment. We have two pre-filled syringe product candidates that have been explored but are being evaluated for discontinuation.
In January 2022, we acquired Lowell Therapeutics, Inc., or Lowell, a privately held company, pursuant to the Agreement and Plan of Merger, dated as of November 14, 2021, or the Merger Agreement, in a transaction for consideration of approximately $32.5 million plus net cash acquired and certain other adjustments, and which included up to approximately $26.0 million of contingent consideration payable in cash or stock at our option, upon the achievement of regulatory and sales-based milestones. In connection with the Merger Agreement, we acquired Niyad and LTX-608 (lyophilized vials of nafamostat for infusion into the extracorporeal circuit or direct IV infusion to the patient, respectively), an in-process research and development, or IPR&D, asset. For additional information regarding the Merger Agreement, see Note 4, “Asset Acquisition” to our consolidated financial statements in this Annual Report on Form 10-K.
Talphera, Inc. timeline
- 2005
- 🏁· approximateFounded
- 2008
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2011
- 🔔· approximateInitial public offering on Nasdaq
- 🔔Initial public offering as Acelrx Pharmaceuticals IncFinal prospectus filed with the SEC on 11 February 2011; shares registered for exchange trading on 1 February 2011.
- 2020
- 💰Record revenue of $5 millionFY2020, the highest of the 6 years on record.
- 2023
- ✎Renamed Talphera, Inc.Formerly Acelrx Pharmaceuticals Inc.
Events of Talphera, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,374 (Jan 2020) · #3,622 (Jan 2021) · #4,776 (Jan 2022) · #5,407 (Dec 2022) · #5,273 (Jul 2023) · #4,463 (Jan 2024) · #3,806 (Oct 2026) · #3,811 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 10.5×
- Price / book
- 3.3×
- Free cash flow yield
- -22.4%
- Net margin
- -746.3%
- Operating margin
- -249.6%
- Return on equity
- -236.5%
- Liabilities / assets
- 42.7%
- Net debt
- $-10M
- Revenue growth
- -95.4%
- R&D / revenue
- 20100.0%
- Revenue per employee
- $450 K
- Profit per employee
- $-3.4 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | — | $-13M | $-14M | -47633.3% |
| Dec 2024 | — | — | $-15M | $-13M | — |
| Dec 2023 | $1M | — | $-17M | $-18M | -2830.8% |
| Dec 2022 | — | — | $-25M | $48M | — |
| Dec 2021 | $0M | -93.0% | $-18M | $-35M | -9236.8% |
| Dec 2020 | $5M | +136.7% | $-41M | $-40M | -745.0% |
| Dec 2019 | $2M | +6.5% | $-54M | $-53M | -2324.9% |
| Dec 2018 | $2M | — | $-36M | $-47M | -2193.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-11M | — | — | — | — |
| Dec 2024 | $-13M | $0M | $-13M | — | — |
| Dec 2023 | $-17M | $0M | $-18M | $-1.29 | — |
| Dec 2022 | $-28M | $0M | $-29M | $5.72 | — |
| Dec 2021 | $-30M | $2M | $-32M | $-5.86 | — |
| Dec 2020 | $-39M | $2M | $-40M | $-0.47 | — |
| Dec 2019 | $-51M | $3M | $-55M | $-0.67 | — |
| Dec 2018 | $-29M | $1M | $-30M | $-0.81 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jun 23, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 29, 2026DEF 14AProxy statement
- Mar 23, 202610-KAnnual report · period to Dec 2025
- Mar 23, 20268-KCurrent reportResults of operations
- Mar 16, 20268-KCurrent reportUnregistered share sale
- Mar 13, 20268-KCurrent reportListing notice
Official filings of Talphera, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $5 M
- Operating income
- $-13 M
- Net income
- $-40 M
For year ending December-2025
Balance sheet
- Total assets
- $30 M
- Total liabilities
- $13 M
- Total equity
- $17 M
As of December-2025
Top 51 institutional investors in Talphera, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 4,286,502 | -315,000 (-6.85%) | 8.25% | $5 M | Nov 2, 2026 |
| 2 | Rosalind Advisors, Inc. | 4,134,144 | -1,035,357 (-20.03%) | 7.96% | $5 M | Nov 16, 2026 |
| 3 | Rock Springs Capital Management LP | 3,589,186 | 0 (0.00%) | 6.91% | $4 M | Nov 16, 2026 |
| 4 | Nantahala Capital Management, LLC | 3,492,519 | -3,492,519 (-50.00%) | 6.72% | $4 M | Nov 13, 2026 |
| 5 | Bleichroeder LP | 1,307,787 | 0 (0.00%) | 2.52% | $2 M | Nov 13, 2026 |
| 6 | Vanguard Capital Management LLC | 1,001,645 | +299,768 (+42.71%) | 1.93% | $1 M | Nov 13, 2026 |
| 7 | Cantor Fitzgerald, L. P. | 709,976 | -1,064,986 (-60.00%) | 1.37% | $1 M | Nov 16, 2026 |
| 8 | Geode Capital Management, LLC | 465,423 | +36,361 (+8.47%) | 0.90% | $1 M | Nov 6, 2026 |
| 9 | Caption Management, LLC | 443,118 | -71,851 (-13.95%) | 0.85% | $1 M | Nov 16, 2026 |
| 10 | Diadema Partners LP | 378,037 | +224,474 (+146.18%) | 0.73% | $0 M | Nov 16, 2026 |
| 11 | Almitas Capital LLC | 339,820 | -127,332 (-27.26%) | 0.65% | $0 M | Nov 17, 2026 |
| 12 | Shay Capital LLC | 314,732 | -91,032 (-22.43%) | 0.61% | $0 M | Nov 16, 2026 |
| 13 | Vanguard Fiduciary Trust Co | 222,372 | 0 (0.00%) | 0.43% | $0 M | Nov 13, 2026 |
| 14 | Gsa Capital Partners LLP | 179,573 | -29,782 (-14.23%) | 0.35% | $0 M | Nov 16, 2026 |
| 15 | Renaissance Technologies LLC | 149,800 | +36,500 (+32.22%) | 0.29% | $0 M | Nov 12, 2026 |
| 16 | Susquehanna International Group, LLP | 123,601 | +47,910 (+63.30%) | 0.24% | $0 M | Nov 16, 2026 |
| 17 | Citadel Advisors LLC | 118,341 | New | 0.23% | $0 M | Nov 16, 2026 |
| 18 | Mariner, LLC | 105,000 | +5,000 (+5.00%) | 0.20% | $0 M | Nov 12, 2026 |
| 19 | Jane Street Group, LLC | 103,202 | +92,548 (+868.67%) | 0.20% | $0 M | Nov 12, 2026 |
| 20 | Universal- Beteiligungs- und Servicegesellschaft mbH | 100,000 | +50,000 (+100.00%) | 0.19% | $0 M | Nov 10, 2026 |
| 21 | Persistent Asset Partners Ltd | 95,987 | +57,019 (+146.32%) | 0.18% | $0 M | Nov 13, 2026 |
| 22 | BlackRock, Inc. | 91,548 | 0 (0.00%) | 0.18% | $0 M | Nov 13, 2026 |
| 23 | Northern Trust Corp | 88,296 | 0 (0.00%) | 0.17% | $0 M | Nov 16, 2026 |
| 24 | HRT Financial LP | 88,216 | New | 0.17% | $0 M | Nov 13, 2026 |
| 25 | Values First Advisors, Inc. | 78,273 | -1,412 (-1.77%) | 0.15% | $0 M | Oct 23, 2026 |
Show all 51: investors 26 to 51
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | XTX Topco Ltd | 68,630 | +40,436 (+143.42%) | 0.13% | $0 M | Nov 16, 2026 |
| 27 | State Street Corp | 22,182 | 0 (0.00%) | 0.04% | $0 M | Nov 12, 2026 |
| 28 | Wealth Enhancement Advisory Services, LLC | 20,000 | +7,500 (+60.00%) | 0.04% | $0 M | Oct 13, 2026 |
| 29 | Stephens Inc /ar/ | 15,133 | 0 (0.00%) | 0.03% | $0 M | Nov 12, 2026 |
| 30 | Choreo, LLC | 13,000 | New | 0.03% | $0 M | Oct 28, 2026 |
| 31 | UBS Group AG | 12,094 | -117,822 (-90.69%) | 0.02% | $0 M | Nov 10, 2026 |
| 32 | Onyx Bridge Wealth Group LLC | 11,500 | 0 (0.00%) | 0.02% | $0 M | Oct 16, 2026 |
| 33 | Welch Group, LLC | 10,000 | New | 0.02% | $0 M | Oct 29, 2026 |
| 34 | Simplex Trading, LLC | 8,434 | New | 0.02% | $0 M | Nov 4, 2026 |
| 35 | Group One Trading LLC | 8,213 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 36 | Vanguard Global Advisers, LLC | 5,467 | -24,194 (-81.57%) | 0.01% | $0 M | Nov 13, 2026 |
| 37 | Steward Partners Investment Advisory, LLC | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 38 | Wells Fargo & Company/mn | 600 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 39 | Tower Research Capital LLC (TRC) | 314 | New | 0.00% | $0 M | Nov 16, 2026 |
| 40 | Osaic Holdings, Inc. | 285 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 41 | FMR LLC | 205 | New | 0.00% | $0 M | Nov 10, 2026 |
| 42 | BNP Paribas Financial Markets | 136 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 43 | SBI Securities Co., Ltd. | 111 | -4 (-3.48%) | 0.00% | $0 M | Oct 22, 2026 |
| 44 | Arax Advisory Partners | 81 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 45 | Morgan Stanley | 46 | +36 (+360.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 46 | Larson Financial Group LLC | 30 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 47 | Flagship Wealth Advisors, LLC | 5 | 0 (0.00%) | 0.00% | $0 M | Nov 3, 2026 |
| 48 | Barclays PLC | 2 | -959 (-99.79%) | 0.00% | $0 M | Nov 6, 2026 |
| 49 | Caitong International Asset Management Co., Ltd | 2 | New | 0.00% | $0 M | Oct 29, 2026 |
| 50 | Citigroup Inc | 1 | New | 0.00% | $0 M | Nov 4, 2026 |
| 51 | Global Retirement Partners, LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Talphera, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 440,104 | $0 M | 0.85% | <0.01% | −0.3% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 261,773 | $0 M | 0.50% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 208,775 | $0 M | 0.40% | <0.01% | +4.7% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 63,382 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 52,389 | $0 M | 0.10% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 16,366 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Talphera, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jill Marie BroadfootDirector | Grant or award | +5,100 | — | — | 13,647 | Form 4 |
| filed | Joseph TodiscoDirector | Grant or award | +5,100 | — | — | 11,497 | Form 4 |
| filed | Marina BozilenkoDirector | Grant or award | +5,100 | — | — | 14,147 | Form 4 |
| filed | Stephen J. HoffmanDirector | Grant or award | +5,100 | — | — | 13,959 | Form 4 |
| filed | Mark A. WanDirector | Grant or award | +5,100 | — | — | 13,959 | Form 4 |
| filed | Adrian AdamsDirector | Grant or award | +5,100 | — | — | 22,709 | Form 4 |
| filed | Abhinav JainDirector | Grant or award | +5,100 | — | — | 12,412 | Form 4 |
| filed | Shakil AslamChief Medical Officer | Shares withheld for tax | -4,518 | $0.820 | $4 K | 76,542 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Talphera, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 462 shares at $1.09
- : 13 shares at $1.07
- : 6,131 shares at $1.05
- : 150 shares at $1.16
- : 341 shares at $1.26
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Talphera, Inc. scorecard#
Passes 2 of the 12 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.3×Price to book 3.3× against Pharmaceutical's median of 3.2×.
- ✗Price to sales below its peers' median10.5×Price to sales 10.5× against Pharmaceutical's median of 3.5×.
- ✗Free cash flow yield above 5%-22.4%Free cash flow is -22.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✓Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against -$40 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-114.1%-114.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities5.5×Current ratio 5.49 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-20.34Z-score -20.34 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Talphera, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.0—100% | 0−100%— | 0.7—100% | 0r1.8−100%— | 2.8−48.0%100% | 5.4+137%100% | 2.3+6.4%100% | 2.2−73.1%100% | 8.0−53.9%100% | 17—100% | |
| Cost of revenue | — | — | — | 2.6−31.0%— | 3.8−37.8%133% | 6.0−11.4%111% | 6.8+71.2%297% | 4.0−62.7%185% | 11−13.4%133% | 12—71.0% | |
| Research and development | 6.0−10.2%21546% | 6.7+21.1%— | 5.5+66.0%852% | 3.3r5.2−18.4%— | 4.1+1.9%145% | 4.0−13.8%74.2% | 4.7−64.5%204% | 13−32.3%611% | 19−9.3%243% | 21—123% | |
| Selling, general and administrative | 7.5−12.4%26711% | 8.5−28.8%— | 12−29.5%1842% | 17r26−45.0%— | 31−14.8%1098% | 36−19.3%671% | 45+117%1967% | 21+25.0%965% | 17—208% | — | |
| General and administrative | — | — | — | — | — | — | — | 21+25.0%965% | 17+6.5%208% | 16—89.9% | |
| Operating expenses | — | — | — | — | — | — | — | 38−18.9%1761% | 47−5.3%584% | 49—284% | |
| Total costs and expenses | 14−11.4%48257% | 15−13.0%— | 18−30.7%2694% | 25r38−34.8%— | 39−16.4%1376% | 46−17.9%856% | 56+49.1%2468% | 38−18.9%1761% | 47—584% | — | |
| Operating income | −13—−48157% | −15—— | −17—−2594% | −25r−37—— | −36—−1276% | −41—−756% | −54—−2368% | −36—−1661% | −39—−484% | −32—−184% | |
| Interest expense and finance costs | — | 0−100%— | 0.1−88.0%20.6% | 1.1r1.2−51.3%— | 2.3−30.7%81.3% | 3.3+30.4%61.0% | 2.5+14.3%111% | 2.2−33.1%103% | 3.3+19.7%41.5% | 2.8—16.0% | |
| Other non-operating income (expense) | −0.9−139%−3139% | 2.2−65.9%— | 6.6−92.2%1014% | 84r84+9594%— | 0.9+48.1%30.9% | 0.6−39.3%10.9% | 1.0—42.3% | −11—−531% | −14—−169% | −11—−64.7% | |
| Income before tax | — | — | −10−117%−1580% | 59r48—— | −35—−1245% | −40—−745% | −53—−2326% | −47—−2192% | −52—−653% | −43—−249% | |
| Income tax | 0—0.0% | 0—— | 0−100%0.0% | 0.0+160%— | 0.0+25.0%0.2% | 0.0+33.3%0.1% | 0.0+50.0%0.1% | 0.0—0.1% | −0.7—−8.8% | −0.0—−0.2% | |
| Income from continuing operations | −14—−51296% | −13—— | −10−117%−1580% | 59—— | — | — | — | — | — | — | |
| Income from discontinued operations | 0.1—261% | 0—— | −8.1—−1246% | −11—— | — | — | — | — | — | — | |
| Net income attributable to shareholders | −14—−51036% | −13—— | −18−139%−2826% | 48—— | −35—−1246% | −40—−746% | −53—−2326% | −47—−2192% | −52—−644% | −43—−249% | |
| Earnings per share, basic | -0.34—— | -0.50—— | -1.29−123%— | 5.73—— | -5.86r-0.29—— | -0.47—— | -0.67—— | -0.81—— | -1.10—— | -0.95—— | |
| Earnings per share, diluted | — | — | -1.29−123%— | 5.72—— | -5.86r-0.29—— | -0.47—— | -0.67—— | -0.81—— | -1.10—— | -0.95—— | |
| Shares, weighted average (basic) | 42+64.1%— | 26+81.2%— | 14+93.1%— | 7.4+23.2%— | 6.0—— | — | — | — | 47+3.5%— | 45—— | |
| Shares, weighted average (diluted) | — | — | 14+92.6%— | 7.4+23.6%— | 6.0r120−93.0%— | 85+7.7%— | 79+35.6%— | 58+24.6%— | 47+3.5%— | 45—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 5.9−33.5%19.8% | 8.9+54.9%48.6% | 5.7−62.5%28.1% | 15+99.3%32.2% | 7.7r13−65.6%9.8% | 22r27+51.7%33.6% | 15−83.3%16.1% | 88+66.3%73.0% | 53−34.1%70.0% | 80—80.3% | |
| Short-term investments | 14—48.7% | 0−100%0.0% | 3.7+639%17.9% | 0.5−98.7%1.0% | 39+150%50.0% | 16−69.7%23.5% | 51+190%56.3% | 18+134%14.7% | 7.6—10.0% | — | |
| Receivables | — | — | — | 0.3+93.1%0.7% | 0.2−74.8%0.2% | 0.6+47.0%1.0% | 0.4+782%0.5% | 0.0−96.8%0.0% | 1.5−73.7%2.0% | 5.8—5.8% | |
| Inventory | — | — | — | 1.2+6.0%2.5% | 1.1−31.7%1.4% | 1.6−50.7%2.5% | 3.3+286%3.6% | 0.9−10.7%0.7% | 1.0−55.6%1.3% | 2.2—2.2% | |
| Other current assets | 0.5−6.3%1.7% | 0.6−74.8%3.0% | 2.2r2.2+17.7%10.8% | 1.9r2.3−27.9%3.9% | 2.6+53.8%3.3% | 1.7−7.7%2.5% | 1.8r1.7+78.1%2.0% | 1.0+125%0.8% | 0.5−39.8%0.6% | 0.8—0.8% | |
| Current assets | 21+122%70.3% | 9.4−18.7%51.6% | 12r12−52.9%56.8% | 25−51.3%51.7% | 50r55+7.8%64.8% | 47−34.7%70.6% | 72−33.6%78.5% | 108+70.3%89.6% | 63−28.8%83.9% | 89—89.1% | |
| Property, plant and equipment | — | — | — | 10−35.6%21.6% | 16+1.7%20.4% | 16+7.6%23.6% | 15+26.7%15.9% | 11+3.9%9.5% | 11+3.2%14.6% | 11—10.7% | |
| Right-of-use (leased) assets | — | — | — | 0.1r3.6−97.8%0.2% | 4.3+36.6%5.5% | 3.2−19.8%4.8% | 3.9—4.3% | — | — | — | |
| Other intangible assets | 8.80.0%29.7% | 8.80.0%48.4% | 8.80.0%43.2% | 8.8—18.6% | 0—0.0% | — | — | — | — | — | |
| Total assets | 30+63.0%100% | 18−10.6%100% | 20−57.1%100% | 47−39.0%100% | 78+17.5%100% | 66−27.4%100% | 91−24.2%100% | 121+59.5%100% | 76−24.4%100% | 100—100% | |
| Accounts payable | 0.5−18.8%1.8% | 0.7−49.9%3.7% | 1.3+6.4%6.6% | 1.3r2.0−40.8%2.6% | 2.1−22.5%2.7% | 2.7+59.1%4.1% | 1.7−16.9%1.9% | 2.1+45.4%1.7% | 1.4−8.6%1.9% | 1.6—1.6% | |
| Debt due within a year | — | — | 0−100%0.0% | 5.4r5.8−39.0%11.3% | 8.8+0.7%11.3% | 8.7+88.7%13.2% | 4.6−46.2%5.1% | 8.6+11.4%7.1% | 7.7+165%10.2% | 2.9—2.9% | |
| Current liabilities | 3.8+43.9%12.8% | 2.6−41.3%14.5% | 4.5−67.2%22.1% | 14−25.6%29.0% | 19+5.0%23.8% | 18+29.6%26.6% | 14−14.5%14.9% | 16+16.6%13.2% | 14+34.0%18.1% | 10—10.2% | |
| Long-term debt | — | — | — | 0−100%0.0% | 5.0−61.9%6.4% | 13−36.0%19.8% | 21+507%22.5% | 3.4−70.3%2.8% | 11−39.0%15.0% | 19—18.6% | |
| Lease liabilities (non-current) | — | — | — | 3.0−21.1%6.2% | 3.8+43.9%4.8% | 2.6−28.4%3.9% | 3.6—4.0% | — | — | — | |
| Total liabilities | 13+23.9%42.7% | 10+62.7%56.1% | 6.3−75.5%30.8% | 26−77.4%54.1% | 114−6.8%146% | 122−8.1%184% | 133+14.2%145% | 116+3.8%96.5% | 112+6.4%148% | 105—105% | |
| Retained earnings | −472—−1587% | −457—−2507% | −444—−2178% | −426—−897% | −474—−608% | −438—−661% | −398—−436% | −345—−286% | −298—−394% | −246—−246% | |
| Shareholders' equity | 17+113%57.3% | 8.0−43.3%43.9% | 14−35.3%69.2% | 22—45.9% | −36—−46.1% | −56—−84.1% | −41−1074%−45.3% | 4.3—3.5% | −37—−48.3% | −5.3—−5.3% | |
| Total liabilities and equity | 30+63.0%100% | 18−10.6%100% | 20−57.1%100% | 47−39.0%100% | 78+17.5%100% | 66−27.4%100% | 91−24.2%100% | 121+59.5%100% | 76−24.4%100% | 100—100% | |
| Shares outstanding | 49+190%— | 17+0.5%— | 17r17+106%— | 8.2+20.5%— | 6.8r137−93.1%— | 99+24.2%— | 80+1.0%— | 79+54.7%— | 51+12.3%— | 45—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | 0−100%— | 0.3−81.1%47.8% | 1.6−16.5%— | 2.0+6.5%70.0% | 1.9+11.1%34.2% | 1.7+190%72.9% | 0.6−67.0%26.7% | 1.7−15.0%21.8% | 2.1—11.8% | |
| Share-based compensation | 0.7−29.3%2496% | 1.0−42.8%— | 1.7−40.2%266% | 2.9−37.3%— | 4.6+4.2%164% | 4.4−12.5%81.7% | 5.1−2.1%221% | 5.2+20.4%240% | 4.3−4.1%53.7% | 4.5—25.8% | |
| Cash from operating activities | −11—−40586% | −13—— | −17—−2687% | −28—— | −30—−1065% | −39—−711% | −51—−2236% | −29—−1352% | −30—−372% | −29—−169% | |
| Capital expenditure | — | 0—— | −0.1—−15.4% | −0.4—— | −1.8—−64.8% | −1.9—−34.3% | −3.5—−152% | −0.8—−38.1% | −2.4—−30.1% | −3.7—−21.4% | |
| Acquisitions, net of cash acquired | — | — | 0—0.0% | −1.7—— | −0.8—−29.1% | — | — | — | — | — | |
| Cash from investing activities | −14−479%−51232% | 3.8—— | −0.5−101%−81.1% | 36—— | −26−177%−927% | 34—630% | −37—−1597% | −11—−506% | −10.0−651%−125% | 1.8—10.4% | |
| Debt issued | — | — | — | — | — | 0−100%0.0% | 25—1092% | 0—0.0% | — | — | |
| Debt repaid | — | 0—— | −5.4—−832% | −8.4—— | −8.8—−313% | −4.7—−86.2% | −3.5—−152% | −7.7—−359% | −3.5—−44.0% | — | |
| Shares issued | — | — | — | — | 45+110%1587% | 21+1630%394% | 1.2−98.5%53.9% | 82+419%3790% | 16—196% | — | |
| Cash from financing activities | 23+88.8%81214% | 12+247%— | 3.5—532% | −0.5−101%— | 42+145%1473% | 17+17.3%313% | 14−80.7%631% | 75+509%3488% | 12—154% | −0.0—−0.1% | |
| Change in cash | −3.0−194%−10604% | 3.1—— | −15−291%−2236% | 7.6—— | −15−216%−518% | 13—232% | −73−309%−3202% | 35—1631% | −27—−343% | −28—−159% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0−100%— | 0−100%— | 0—— | 0−100%— | 0*—— | 0.0—100% | 0—— | 0.0—100% | 0*−100%— | 0—— | 0—— | 0—— | 0.3*—100% | |
| Research and development | 7.1+22.3%— | 2.2+21.4%— | 1.7+12.7%— | 1.7+41.1%— | 1.6*+18.0%— | 1.8−12.2%180300% | 1.5−21.4%— | 1.2−18.4%4330% | 1.3*−25.2%— | 2.1—— | 1.9—— | 1.4—— | 1.8*—630% | |
| Selling, general and administrative | 8.4+15.3%— | 1.9+20.2%— | 2.2+1.9%— | 2.3+29.5%— | 1.9*+13.1%— | 1.6−4.5%162000% | 2.2−7.1%— | 1.8−36.7%6570% | 1.7*−40.1%— | 1.7—— | 2.4—— | 2.8—— | 2.8*—995% | |
| Total costs and expenses | 15+18.4%— | 4.1+20.8%— | 3.9+6.3%— | 3.9+34.1%— | 3.5*+15.3%— | 3.4−8.7%342300% | 3.7−13.5%— | 2.9−30.5%10900% | 3.0*−34.4%— | 3.7—— | 4.3—— | 4.2—— | 4.6*—1624% | |
| Operating income | −15—— | −4.1—— | −3.9—— | −3.9—— | −3.5*—— | −3.4—−342200% | −3.7—— | −2.9—−10800% | −3.0*—— | −3.7—— | −4.3—— | — | — | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | 0*—— | 0—— | 0—— | 0—— | 0*—0.0% | |
| Other non-operating income (expense) | 0.8+41.9%— | 0.1—— | −0.4−290%— | 1.4+457%— | −0.3*−128%— | −1.0−356%−101400% | 0.2−54.0%— | 0.3−11.7%926% | 1.1*—— | 0.4—— | 0.4—— | 0.3—— | −0.2*—−80.8% | |
| Income before tax | — | — | — | — | — | — | — | — | — | −3.4—— | −3.8—— | — | −4.5*—−1605% | |
| Income tax | — | — | — | — | — | — | — | — | 0*—— | 0—— | 0—— | — | −0.0*—−1.8% | |
| Income from continuing operations | −15—— | −4.0—— | −4.3—— | −2.6—— | −3.8*—— | −4.4—−443600% | −3.5—— | −2.7—−9874% | −1.9*—— | −3.4—— | −3.8—— | −4.0—— | −4.5*—−1603% | |
| Income from discontinued operations | 0−100%— | 0—— | 0—— | 0−100%— | 0*—— | 0—0.0% | 0—— | 0.1—270% | 0*—— | 0—— | 0—— | 0—— | −0.0*—−4.3% | |
| Net income attributable to shareholders | −15—— | −4.0—— | −4.3—— | −2.6—— | −3.8*—— | −4.4—−443600% | −3.5—— | −2.6—−9604% | −1.9*—— | −3.4—— | −3.8—— | −4.0—— | −4.5*—−1607% | |
| Earnings per share, basic | — | -0.05—— | -0.06—— | -0.04—— | — | -0.11—— | -0.10—— | -0.10—— | — | -0.13—— | -0.15—— | -0.16—— | — | |
| Earnings per share, diluted | — | — | — | — | — | — | — | -0.10—— | — | — | — | -0.16—— | — | |
| Shares, weighted average (basic) | 76+82.2%— | 76+82.2%— | 76+119%— | 70+166%— | — | 41+58.1%— | 35+31.8%— | 26+6.3%— | — | 26—— | 26—— | 25—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 11—45.2% | 11+208%45.2% | 0.7−89.1%2.8% | 3.8−29.0%12.7% | 5.9−33.5%19.8% | 3.5−68.9%11.2% | 6.8−49.4%41.1% | 5.4−55.6%35.9% | 8.9+54.9%48.6% | 11—52.9% | 13—54.0% | 12—42.1% | 5.7—28.1% | |
| Short-term investments | 3.5—14.8% | 3.5−80.4%14.8% | 16—60.9% | 17—57.3% | 14—48.7% | 18—58.0% | — | — | 0−100%0.0% | 0—0.0% | 0.6—2.4% | 6.5—22.5% | 3.7—17.9% | |
| Other current assets | 0.6—2.5% | 0.6−5.7%2.5% | 0.9+0.7%3.4% | 0.2−71.1%0.8% | 0.5−6.3%1.7% | 0.6−41.2%2.1% | 0.9−55.1%5.5% | 0.8−42.4%5.3% | 0.6−74.8%3.0% | 1.1—5.1% | 2.0—8.1% | 1.4—4.8% | 2.2r2.2—10.8% | |
| Current assets | 15—62.6% | 15−32.7%62.6% | 18+134%67.1% | 21+245%70.8% | 21+122%70.3% | 22+79.8%71.3% | 7.7−52.0%46.6% | 6.2−69.0%41.2% | 9.4−18.7%51.6% | 12—58.0% | 16—64.5% | 20—69.3% | 12r12—56.8% | |
| Other intangible assets | 8.8—37.4% | 8.80.0%37.4% | 8.80.0%32.9% | 8.80.0%29.2% | 8.80.0%29.7% | 8.80.0%28.7% | 8.80.0%53.4% | 8.80.0%58.8% | 8.80.0%48.4% | 8.8—42.0% | 8.8—35.5% | 8.8—30.7% | 8.8—43.2% | |
| Total assets | 24—100% | 24−23.3%100% | 27+62.3%100% | 30+101%100% | 30+63.0%100% | 31+46.3%100% | 17−33.6%100% | 15−47.9%100% | 18−10.6%100% | 21—100% | 25—100% | 29—100% | 20—100% | |
| Accounts payable | 0.7—2.9% | 0.7+28.1%2.9% | 0.4−53.7%1.4% | 0.9+184%3.1% | 0.5−18.8%1.8% | 0.5+32.8%1.7% | 0.8+3.3%5.1% | 0.3−74.4%2.2% | 0.7−49.9%3.7% | 0.4—1.9% | 0.8—3.3% | 1.3—4.4% | 1.3—6.6% | |
| Debt due within a year | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Current liabilities | 4.6—19.6% | 4.6+44.1%19.6% | 4.2+59.2%15.6% | 4.0+102%13.3% | 3.8+43.9%12.8% | 3.2+16.3%10.4% | 2.6−19.7%15.9% | 2.0−40.5%13.3% | 2.6−41.3%14.5% | 2.8—13.1% | 3.3—13.2% | 3.3—11.6% | 4.5—22.1% | |
| Total liabilities | 13—54.6% | 13+11.2%54.6% | 12+25.4%46.3% | 12+24.3%38.7% | 13+23.9%42.7% | 12+1.7%37.6% | 9.9−18.5%59.9% | 9.4−24.5%62.7% | 10+62.7%56.1% | 11—54.1% | 12—48.8% | 12—43.2% | 6.3—30.8% | |
| Retained earnings | −482—−2046% | −482—−2046% | −478—−1785% | −474—−1572% | −472—−1587% | −468—−1522% | −463—−2805% | −460—−3067% | −457—−2507% | −455—−2167% | −452—−1819% | −448—−1558% | −444—−2178% | |
| Shareholders' equity | 11—45.4% | 11−44.1%45.4% | 14+117%53.7% | 18+230%61.3% | 17+113%57.3% | 19+98.9%62.4% | 6.6−47.9%40.1% | 5.6−65.7%37.3% | 8.0−43.3%43.9% | 9.6—45.9% | 13—51.2% | 16—56.8% | 14—69.2% | |
| Total liabilities and equity | 24—100% | 24−23.3%100% | 27+62.3%100% | 30+101%100% | 30+63.0%100% | 31+46.3%100% | 17−33.6%100% | 15−47.9%100% | 18−10.6%100% | 21—100% | 25—100% | 29—100% | 20—100% | |
| Shares outstanding | 52—— | 52+14.0%— | 52+153%— | 50+193%— | 49+190%— | 46+168%— | 21+20.8%— | 17+0.6%— | 17+0.5%— | 17—— | 17—— | 17—— | 17r17—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | 0*—— | 0*—— | 0*—— | 0—— | 0*—0.0% | |
| Share-based compensation | 0.9+25.5%— | 0.3+92.1%— | 0.2+46.4%— | 0.2+9.2%— | 0.2*−19.6%— | 0.2−35.0%15200% | 0.2−25.6%— | 0.2−35.1%726% | 0.2*−26.0%— | 0.2—— | 0.2—— | 0.3—— | 0.3*—111% | |
| Cash from operating activities | −13—— | −3.0*—— | −3.9*—— | −3.4—— | −2.4*—— | −2.5*—−251000% | −2.9*—— | −3.5—−12852% | −2.3*—— | −2.9*—— | −4.6*—— | −2.9—— | −3.9*—−1405% | |
| Capital expenditure | — | — | — | — | — | — | — | — | 0*—— | 0*—— | 0*—— | 0—— | 0*—0.0% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from investing activities | 15—— | 13*—— | 1.1*—— | −2.7—— | 3.5*—— | −18*−3069%−1781500% | 0*−100%— | 0—0.0% | 0*—— | 0.6*—— | 5.9*—— | −2.7—— | −3.7*—−1299% | |
| Debt repaid | — | — | — | — | — | — | — | — | 0*—— | 0*—— | 0*—— | 0—— | 0*—0.0% | |
| Cash from financing activities | 5.2−75.5%— | 0.0*−99.8%— | −0.3*−106%— | 4.0—— | 1.4*—— | 17*+56537%1699100% | 4.4*—— | −0.0−100%−18.5% | 0*—— | 0.0*—— | 0*—— | 12—— | −0.1*—−24.2% | |
| Change in cash | 7.2—— | 9.9*—— | −3.1*−320%— | −2.1—— | 2.4*—— | −3.3*—−333400% | 1.4*+7.8%— | −3.5−154%−12870% | −2.3*—— | −2.3*—— | 1.3*—— | 6.4—— | −7.7*—−2729% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Talphera, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $1.1 M | $1.5 M | $691 K | $50 |
| 2024Chief executive | $1.0 M | $845 K | $643 K | $23 |
| 2023Chief executive | $1.2 M | $1.0 M | $778 K | $33 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Talphera, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 4 · Directors and officers 5 · Material agreement 3 · Unregistered share sale 4 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Unregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersResults announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2025 | $17 M | Private placement after listing | $10 to $50 million | 13 | equity, options | SEC |
| Apr 2025 | $5 M | Private placement after listing | $2 to $10 million | 11 | equity, options | SEC |
| Jan 2024 | $6 M | Private placement after listing | $2 to $10 million | 6 | options | SEC |
| Jul 2023 | $10 M | Private placement after listing | $10 to $50 million | 10 | equity, options | SEC |
| Jan 2022 | $5 M | Private placement after listing | $2 to $10 million | 32 | equity | SEC |
| Jun 2012 | $10 M | Private placement after listing | $10 to $50 million | 10 | equity, options | SEC |
| Jun 2011 | $21 M | No. 3 | $10 to $50 million | 2 | debt, options | SEC |
| Sep 2010 | $8 M | No. 2 | $2 to $10 million | 8 | debt, options | SEC |
| Nov 2009 | $15 M | No. 1 | $10 to $50 million | 8 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015 | · | · | 19 | · | · | · | · | · | · | · | · | · | 19 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 19 people (36% of workforce) | Restructuring planSEC 8-K | “The cost reduction plan will reduce the Company’s workforce by 19 employees, approximately 36% of total headcount, in the first quarter of 2015.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Talphera, Inc. compares in Pharmaceutical
- Market cap$57 M · higher than 13% of 393
- Revenue$5 M · higher than 6% of 324
- Net margin-746.3% · higher than 0% of 313
- Price / sales10.5× · lower than 10% of 219
- Price / book3.3× · lower than 34% of 207
- FCF yield-22.4% · higher than 15% of 69
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Talphera, Inc.🇺🇸 | $57 M | — | -746.3% | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Korea United Pharm Inc.$191 M
- Suheung Co., Ltd.$199 M
- JW Holdings Corporation$206 M
- Hester Biosciences Limited$214 M
- Venus Remedies Limited$215 M
- Windlas Biotech Limited$217 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, value.today research, SEC filing.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Talphera, Inc.? Verify and update this profile — free
Show Talphera, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.